Jul 8, 10:56 AM EDT
Arcutis gets FDA review for Zoryve 0.05% label expansion
ARQT
Arcutis Biotherapeutics ( ARQT ) announced on Wednesday that the U.S. FDA accepted a supplemental New Drug Application for expanding the label of its Zoryve 0.05% cream for infants with atopic dermatitis, also known as eczema. The treatment is already availabl…